Trials Sponsors Conditions Drugs Pricing

Conditions

Stage IIb Breast Cancer (T3N0)Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)

Outcome Measures

Primary Outcomes (1)

Proportion of patients upstaged to Stage IV disease
Proportion of patients upstaged to Stage IV disease as a result of the imaging study, between the groups
Within 30 days from date of randomization

Secondary Outcomes (6)

Proportion of patients who receive multimodal therapy of curative intent
Within 12 months from date of randomization
Number of additional tests, such as imaging and biopsy, resulting from findings of study imaging
Within 12 months from date of randomization
Prognostic ability of PET SUV of the primary lesion on the pathological response rate to neo-adjuvant chemotherapy
Within 12 months from date of randomization
Disease Free Survival
From date of randomization to date of event, assessed up to 5 years
Overall Survival
From date of randomization to date of event, assessed up to 5 years
+1 more secondary outcomes

Study Arms (2)

Whole-body FDG PET-CT alone

EXPERIMENTAL

Other: Whole-body FDG PET-CT alone

Conventional breast cancer staging

NO INTERVENTION

Conventional breast cancer staging consisting of a bone scan and CT imaging with contrast of the chest / abdomen \& pelvis

Interventions

Whole-body FDG PET-CT aloneOther

FDG PET-CT imaging

Whole-body FDG PET-CT alone

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Women (or men) with histological evidence of breast cancer for whom potentially curative treatment is planned.
Based on clinical information (physical exam, imaging):

Sponsors & Collaborators

Cancer Care Ontario
Othercollaborator
Ontario Clinical Oncology Group (OCOG)
Otherlead

Study Sites (6)

Juravinski Cancer Centre

Hamilton, Ontario, L8V 5C2, Canada

London Regional Cancer Program

London, Ontario, N6A 4L6, Canada

Ottawa Hospital Regional Cancer Centre

Ottawa, Ontario, K1H 8L6, Canada

Thunder Bay Regional Health Sciences Centre

Thunder Bay, Ontario, P7B 6V4, Canada

Sunnybrook Odette Cancer Centre

Toronto, Ontario, M4N 3M5, Canada

Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada

Related Publications (3)

Metser U, Dayes IS, Parpia S, Eisen AF, Hodgson N, Cil TD, George R, Blanchette P, Arnaout A, Chan A, Levine MN. Prospective study on 18F-FDG PET-CT for staging locally advanced invasive lobular breast carcinoma. Br J Cancer. 2026 May;134(10):1387-1392. doi: 10.1038/s41416-026-03362-9. Epub 2026 Mar 2.
PMID: 41772273DERIVED
Metser U, Ali Mirshahvalad S, Dayes IS, Parpia S, Levine MN. 18F-FDG PET/CT of Oligometastatic Disease in Locally Advanced Breast Cancer: PETABC Trial Post Hoc Analysis. Radiology. 2025 Aug;316(2):e243788. doi: 10.1148/radiol.243788.
PMID: 40762843DERIVED

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

Ian Dayes, MD
Juravinski Hospital and Cancer Centre
PRINCIPAL INVESTIGATOR
Andrea Eisen, MD
Sunnybrook Health Sciences Centre
PRINCIPAL INVESTIGATOR
Ralph George, MD
St. Michael's Hospital, CIBC Breast Centre
PRINCIPAL INVESTIGATOR
Ur Metser, MD
Princess Margaret Hospital, Canada
PRINCIPAL INVESTIGATOR

Enrollment

369 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: NONE
Purpose: DIAGNOSTIC
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

April 15, 2016

First Posted

April 26, 2016

Study Start

December 6, 2016

Actual (reported)

Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (6)

Study Arms (2)

Whole-body FDG PET-CT alone

Conventional breast cancer staging

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (6)

Related Publications (3)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (6)

Study Arms (2)

Whole-body FDG PET-CT alone

Conventional breast cancer staging

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (6)

Related Publications (3)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations